MYADM and lung carcinoma: Other stronger correlations were that of MAL (LUAD) and MYADM (LUSC) in lung cancer, which was the second most highly ranked in the 2020 ranking, with 12.5% of the new cancer cases, and that of MAL2 and MALL in PAAD, which was ranked twelfth, with 2.7% of the new cases.